Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 16;23(4):2201. doi: 10.3390/ijms23042201

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effects of losartan, mirabegron, and their combination on diastolic dysfunction in DOXO-induced chronic cardiotoxicity assessed by echocardiography at week 8. Values are presented as mean ± S.E.M., * p < 0.05 vs. control group, # p < 0.05 vs. DOXO-only group (n = 6–9, one-way ANOVA or ANOVA on ranks in the case of E/e’, Holm-Sidak post hoc test). (a) representative pulse wave Doppler (PWD) and tissue Doppler (TD) images, (b) mitral valve early flow velocity (E) to septal mitral annulus velocity (e’) ratio (E/e’), (c) mitral valve early flow velocity (E), (d) septal mitral annulus velocity (e’), and (e) isovolumic relaxation time (IVRT). DOXO: doxorubicin, L: losartan, M: mirabegron.